Cited by 1,305interferon and immune responsesImmunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

The DOI matches its Crossref record; 128 of the 128 references it cites were found in a registry or an index.

Type I interferons in anticancer immunity

Zitvogel, Laurence, Galluzzi, Lorenzo, Kepp, Oliver, Smyth, Mark J., Kroemer, Guido·2015·Nature Reviews Immunology

Open this paper in CoChat — free account

Abstract

Type I interferons (IFNs) are known for their key role in antiviral immune responses. In this Review, we discuss accumulating evidence indicating that type I IFNs produced by malignant cells or tumour-infiltrating dendritic cells also control the autocrine or paracrine circuits that underlie cancer immunosurveillance. Many conventional chemotherapeutics, targeted anticancer agents, immunological adjuvants and oncolytic viruses are only fully efficient in the presence of intact type I IFN signalling. Moreover, the intratumoural expression levels of type I IFNs or of IFN-stimulated genes correlate with favourable disease outcome in several cohorts of patients with cancer. Finally, new anticancer immunotherapies are being developed that are based on recombinant type I IFNs, type I IFN-encoding vectors and type I IFN-expressing cells.

Integrity signals

Registry

Crossref · 10.1038/nri3845

Cites

128 of 128 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
Kawai, T., & Akira, S. (2010) · Nature Immunology · doi:10.1038/ni.1863 · Cited by 9,304
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Self-citation
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Virus interference. I. the interferon
Isaacs, A., & Lindenmann, J. (1957) · Proceedings of the Royal Society of London. Series B - Biological Sciences · doi:10.1098/rspb.1957.0048 · Cited by 3,451
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,235
Type I interferons in infectious disease
McNab, F., Mayer-Barber, K., Sher, A., Wack, A., & O'Garra, A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3787 · Cited by 2,780
STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors
Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.-D., Mauceri, H., Beckett, M., Darga, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.019 · Cited by 2,182
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
Woo, S.-R., Fuertes, M. B., Corrales, L., Spranger, S., Furdyna, M. J., Leung, M. Y. K., Duggan, R., Wang, Y., Barber, G. N., Fitzgerald, K. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.017 · Cited by 1,917

Flagged first, then by citations

Show all 128 references

Sorted by citations

Items 201–300 of 1,000

Impaired function of dendritic cells within the tumor microenvironment
Xiao, Z., Wang, R., Wang, X., Yang, H., Dong, J.-M., He, X., Yang, Y., Guo, J., Cui, J., & Zhou, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1213629 · Cited by 105
The crucial regulatory role of type I interferon in inflammatory diseases
Ji, L., Li, T., Chen, H., Yang, Y., Liu, J., Liu, J., Qiao, W., & Chen, H. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01188-z · Cited by 107
Clostridium butyricum therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitors
Tomita, Y., Goto, Y., Sakata, S., Imamura, K., Minemura, A., Oka, K., Hayashi, A., Jodai, T., Akaike, K., Anai, M., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2081010 · Cited by 100
Molecular and Structural Basis of DNA Sensors in Antiviral Innate Immunity
Zahid, A., Ismail, H., Li, B., & Jin, T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.613039 · Cited by 100
Self-dsDNA in the pathogenesis of systemic lupus erythematosus
Bai, Y., Tong, Y., Liu, Y., & Hu, H. (2017) · Clinical & Experimental Immunology · doi:10.1111/cei.13041 · Cited by 104
Radiation‐Induced Immunogenic Cell Death for Cancer Radioimmunotherapy
Liu, T., Pei, P., Shen, W., Hu, L. T., & Yang, K. (2023) · Small Methods · doi:10.1002/smtd.202201401 · Cited by 104
Polymerization Induced Self-Assembly of a Site-Specific Interferon α-Block Copolymer Conjugate into Micelles with Remarkably Enhanced Pharmacology
Liu, X., Sun, M., Sun, J., Hu, J., Wang, Z., Guo, J., & Gao, W. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b06013 · Cited by 99
Polycarbonate-based ultra-pH sensitive nanoparticles improve therapeutic window
Wang, X., Wilhelm, J., Li, W., Li, S., Wang, Z., Huang, G., Wang, J., Tang, H., Khorsandi, S., Sun, Z., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19651-7 · Cited by 99
Pan‐cancer analysis of copy number changes in programmed death‐ligand 1 (PD‐L1, CD274) – associations with gene expression, mutational load, and survival
Budczies, J., Bockmayr, M. L., Denkert, C., Klauschen, F., Gröschel, S., Darb‐Esfahani, S., Pfarr, N., Leichsenring, J., Onozato, M. L., Lennerz, J. K., et al. (2016) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22365 · Cited by 99
Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments
Cauwels, A., Lint, S. V., Paul, F., Garcin, G., Koker, S. D., Parys, A. V., Wueest, T., Gerlo, S., der Heyden, J. V., Bordat, Y., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1980 · Cited by 104
A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours
Dredge, K. S., Brennan, T. V., Hammond, E., Lickliter, J. D., Lin, L., Bampton, D., Handley, P., Lankesheer, F., Morrish, G. A., Yang, Y., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0006-0 · Cited by 97
Colorectal Cancer-Infiltrating Regulatory T Cells: Functional Heterogeneity, Metabolic Adaptation, and Therapeutic Targeting
Revilla, S. A., Kranenburg, O., & Coffer, P. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.903564 · Cited by 104
STING Signaling in Melanoma Cells Shapes Antigenicity and Can Promote Antitumor T-cell Activity
Falahat, R., Perez-Villarroel, P., Mailloux, A. W., Zhu, G., Pilon-Thomas, S., Barber, G. N., & Mulé, J. J. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0229 · Cited by 95
Comparison of RT-qPCR and Nanostring in the measurement of blood interferon response for the diagnosis of type I interferonopathies
Pescarmona, R., Bélot, A., Villard, M., Besson, L., Lopez, J., Mosnier, I., Mathieu, A., Lombard, C., Garnier, L., Frachette, C., et al. (2018) · Cytokine · doi:10.1016/j.cyto.2018.10.023 · Cited by 95
NQO1 targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance
Li, X., Liu, Z., Zhang, A., Han, C., Shen, A., Jiang, L., Boothman, D. A., Qiao, J., Wang, Y., Huang, X., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11238-1 · Cited by 95
Antitumor Activity of Extract From the Sporoderm-Breaking Spore of Ganoderma lucidum: Restoration on Exhausted Cytotoxic T Cell With Gut Microbiota Remodeling
Su, J., Su, L., Li, D. X., Shuai, O., Zhang, Y., Liang, H., Jiao, C., Xu, Z., Lai, Y. R., & Xie, Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01765 · Cited by 94
EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer
Gong, K., Guo, G., Panchani, N., Bender, M. E., Gerber, D. E., Minna, J. D., Fattah, F., Gao, B., Peyton, M., Kernstine, K., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0048-0 · Cited by 92
Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study
Marchini, A., Daeffler, L., Pozdeev, V. I., Angelova, A. L., & Rommelaere, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01848 · Cited by 95
T‐cell activation and immune memory enhancement induced by irreversible electroporation in pancreatic cancer
He, C., Huang, X., Zhang, Y. L., Lin, X., & Li, S. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.39 · Cited by 93
Effects of lactate in immunosuppression and inflammation: Progress and prospects
Luo, Y., Li, L., Chen, X., Gou, H., Yan, K., & Xu, Y. (2021) · International Reviews of Immunology · doi:10.1080/08830185.2021.1974856 · Cited by 95
Tumor-Associated Macrophages in Gliomas—Basic Insights and Treatment Opportunities
Andersen, J. K., Miletić, H., & Hossain, J. A. (2022) · Cancers · doi:10.3390/cancers14051319 · Cited by 94
Interventional hydrogel microsphere vaccine as an immune amplifier for activated antitumour immunity after ablation therapy
Liu, X., Zhuang, Y., Huang, W., Wu, Z., Chen, Y., Shan, Q., Zhang, Y., Wu, Z., Ding, X., Qiu, Z., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39759-w · Cited by 91
Nucleic Acid Sensors as Therapeutic Targets for Human Disease
McWhirter, S. M., & Jefferies, C. A. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.004 · Cited by 91
The Role of Plasmacytoid Dendritic Cells in Cancers
Zhou, B., Lawrence, T., & Liang, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.749190 · Cited by 90
IFNAR1 Controls Autocrine Type I IFN Regulation of PD-L1 Expression in Myeloid-Derived Suppressor Cells
Xiao, W. L., Klement, J. D., Lu, C., Ibrahim, M. L., & Liu, K. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800129 · Cited by 90
Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas
Zeng, J., Li, X., Sander, M., Zhang, H., Yan, G., & Lin, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.721830 · Cited by 89
Intratumoral delivery of RIG-I agonist SLR14 induces robust antitumor responses
Jiang, X., Muthusamy, V., Fedorova, O., Kong, Y., Kim, D. J., Bosenberg, M., Pyle, A. M., & Iwasaki, A. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20190801 · Cited by 91
Cowpea Mosaic Virus Nanoparticles and Empty Virus-Like Particles Show Distinct but Overlapping Immunostimulatory Properties
Wang, C., Beiss, V., & Steinmetz, N. F. (2019) · Journal of Virology · doi:10.1128/jvi.00129-19 · Cited by 89
Immune recognition of irradiated cancer cells
Wennerberg, E., Vanpouille‐Box, C., Bornstein, S., Yamazaki, T., Demaria, S., & Galluzzi, L. (2017) · Immunological Reviews · doi:10.1111/imr.12568 · Cited by 88
Self-citation
Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma
Davar, D., Wang, H., Chauvin, J.-M., Pagliano, O., Fourcade, J. J., Ka, M., Menna, C., Rose, A., Sander, C., Borhani, A. A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00632 · Cited by 86
Spleen-Targeted mRNA Vaccine Doped with Manganese Adjuvant for Robust Anticancer Immunity In Vivo
Luo, Z., Lin, Y., Meng, Y., Li, M., Ren, H., Shi, H., Cheng, Q., & Wei, T. (2024) · ACS Nano · doi:10.1021/acsnano.4c09902 · Cited by 88
Hypoxia Induces Transcriptional and Translational Downregulation of the Type I IFN Pathway in Multiple Cancer Cell Types
Miar, A., Arnaiz, E., Bridges, E., Beedie, S., Cribbs, A. P., Downes, D. J., Beagrie, R., Rehwinkel, J., & Harris, A. L. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2306 · Cited by 86
Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity
Hou, Y., Liang, H. L., Yu, X., Liu, Z., Cao, X., Rao, E., Huang, X., Wang, L., Li, L., Bugno, J., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb0130 · Cited by 85
Critical role of interferons in gastrointestinal injury repair
Constance, M., Espinosa, V., Lin, J.-D., Jianya, P., Raghavendra, S., Dutta, O., Hsiang-Chi, T., Sv, S., Risman, H. P., Sandoval, M. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22928-0 · Cited by 85
Immunomodulatory Role of Interferons in Viral and Bacterial Infections
Mertowska, P., Smolak, K., Mertowski, S., & Grywalska, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210115 · Cited by 91
cGAS-STING signaling in the tumor microenvironment
Liu, Z., Wang, D., Zhang, J., Xiang, P., Zeng, Z., Xiong, W., & Shi, L. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216409 · Cited by 87
Cowpea mosaic virus stimulates antitumor immunity through recognition by multiple MYD88-dependent toll-like receptors
Mao, C., Beiss, V., Fields, J. L., Steinmetz, N. F., & Fiering, S. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120914 · Cited by 87
A Single‐Atom Manganese Nanozyme Mn‐N/C Promotes Anti‐Tumor Immune Response via Eliciting Type I Interferon Signaling
Qiao, W., Chen, J., Zhou, H., Hu, C., Dalangood, S., Li, H., Yang, D., Yang, Y. P., & Gui, J. (2024) · Advanced Science · doi:10.1002/advs.202305979 · Cited by 84
Interferon regulatory factor 1 inactivation in human cancer
Alsamman, K., & El-Masry, O. S. (2018) · Bioscience Reports · doi:10.1042/bsr20171672 · Cited by 86
Type I interferons and endoplasmic reticulum stress in health and disease
(2020) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2019.10.004 · Cited by 83
Neoadjuvant Interferons: Critical for Effective PD-1–Based Immunotherapy in TNBC
Brockwell, N. K., Owen, K. L., Zanker, D. J., Spurling, A., Rautela, J., Duivenvoorden, H. M., Baschuk, N., Caramia, F., Loi, S., Darcy, P. K., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0150 · Cited by 83
The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation
Wolff, F., Leisch, M., Greil, R., Risch, A., & Pleyer, L. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-017-0168-z · Cited by 85
Harnessing radiation to improve immunotherapy: better with particles?
Durante, M., & Formenti, S. C. (2019) · British Journal of Radiology · doi:10.1259/bjr.20190224 · Cited by 85
Beyond Immune Cell Migration: The Emerging Role of the Sphingosine-1-phosphate Receptor S1PR4 as a Modulator of Innate Immune Cell Activation
Olesch, C., Ringel, C., Brüne, B., & Weigert, A. (2017) · Mediators of Inflammation · doi:10.1155/2017/6059203 · Cited by 85
Expansion of amphibian intronless interferons revises the paradigm for interferon evolution and functional diversity
Sang, Y., Liu, Q., Lee, J., Ma, W., McVey, D. S., & Blecha, F. (2016) · Scientific Reports · doi:10.1038/srep29072 · Cited by 81
Bifunctional cancer cell–based vaccine concomitantly drives direct tumor killing and antitumor immunity
Chen, K., Reinshagen, C., van Schaik, T., Rossignoli, F., Borges, P., Mendonca, N. C., Abdi, R., Simon, B. G., Reardon, D. A., Wakimoto, H., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abo4778 · Cited by 81
Laser Therapy Inhibits Tumor Growth in Mice by Promoting Immune Surveillance and Vessel Normalization
Ottaviani, G., Martinelli, V. C., Rupel, K., Caronni, N., Naseem, A., Zandonà, L., Perinetti, G., Gobbo, M., Lenarda, R. D., Bussani, R., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.07.028 · Cited by 80
DNA Tumor Virus Regulation of Host DNA Methylation and Its Implications for Immune Evasion and Oncogenesis
Kuss-Duerkop, S. K., Westrich, J. A., & Pyeon, D. (2018) · Viruses · doi:10.3390/v10020082 · Cited by 80
DAMP—Induced Allograft and Tumor Rejection: The Circle Is Closing
Land, W. G., Agostinis, P., Gasser, S., Garg, A. D., & Linkermann, A. (2016) · American Journal of Transplantation · doi:10.1111/ajt.14012 · Cited by 81
Double-edged effects of interferons on the regulation of cancer-immunity cycle
Zhang, X., Wang, S., Zhu, Y., Zhang, M., Zhao, Y., Yan, Z., Wang, Q., & Li, X. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1929005 · Cited by 80
Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms
Kim, D., Dastidar, H., Zhang, C., Zemp, F. J., Lau, K. C. K., Ernst, M., Rakic, A., Sikdar, S., Rajwani, J., Naumenko, V., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00324-x · Cited by 80
Trial Watch: Immunotherapy plus radiation therapy for oncological indications
Vacchelli, E., Bloy, N., Aranda, F., Buqué, A., Cremer, I., Demaria, S., Eggermont, A. M. M., Formenti, S. C., Fridman, W. H., Fucikova, J. P., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1214790 · Cited by 76
Self-citation
Nanovaccines: An effective therapeutic approach for cancer therapy
Gurunathan, S., Pratheep, T., Wang, L., Cao, Q., & Kim, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115992 · Cited by 78
Adipose type I interferon signalling protects against metabolic dysfunction
Wieser, V. E., Adolph, T. E., Grander, C., Grabherr, F., Enrich, B., Moser, P. L., Moschen, A. R., Kaser, S., & Tilg, H. (2016) · Gut · doi:10.1136/gutjnl-2016-313155 · Cited by 78
Medium dose intermittent cyclophosphamide induces immunogenic cell death and cancer cell autonomous type I interferon production in glioma models
Du, B., & Waxman, D. J. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.11.025 · Cited by 76
DNA methylation repels binding of hypoxia-inducible transcription factors to maintain tumor immunotolerance
D’Anna, F., Dyck, L. V., Xiong, J., Zhao, H., Berrens, R. V., Qian, J., Bieniasz-Krzywiec, P., Chandra, V., Schoonjans, L., Matthews, J. B., et al. (2020) · Genome biology · doi:10.1186/s13059-020-02087-z · Cited by 76
Immune mechanisms mediating abscopal effects in radioimmunotherapy
Rodriguez-Ruiz, M. E., Rodríguez, I., Leaman, O., López‐Campos, F., Montero, A., Conde-Moreno, A. J., Aristu, J., Lara, P. C., Calvo, F. Á., & Melero, I. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.12.002 · Cited by 76
Transcriptional and chromatin regulation in interferon and innate antiviral gene expression
Au-Yeung, N., & Horvath, C. M. (2018) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.10.003 · Cited by 74
MYC functions as a switch for natural killer cell-mediated immune surveillance of lymphoid malignancies
Swaminathan, S., Hansen, A. S., Heftdal, L. D., Dhanasekaran, R., Deutzmann, A., Mahauad‐Fernandez, W. D., Liefwalker, D. F., Horton, C. E., Mosley, A. R., Liebersbach, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16447-7 · Cited by 75
WEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathway
Guo, E., Xiao, R., Wu, Y., Lu, F., Liu, C., Yang, B., Li, X., Fu, Y., Wang, Z., Yuan, L., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20210789 · Cited by 74
Local scaffold-assisted delivery of immunotherapeutic agents for improved cancer immunotherapy
Shang, Q., Dong, Y., Su, Y., Leslie, F., Sun, M., & Wang, F. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114308 · Cited by 74
MLL3 loss drives metastasis by promoting a hybrid epithelial–mesenchymal transition state
Cui, J., Zhang, C., Lee, J., Bartholdy, B., Yang, D., Liu, Y., Erler, P., Galbo, P. M., Hodge, D. Q., Huangfu, D., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-022-01045-0 · Cited by 75
Trial watch: immune checkpoint blockers for cancer therapy
Vanpouille-Box, C., Lhuillier, C., Bezu, L., Aranda, F., Yamazaki, T., Kepp, O., Fucikova, J., Spisek, R., Demaria, S., Formenti, S. C., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1373237 · Cited by 73
Self-citation
The intersection of COVID-19 and cancer: signaling pathways and treatment implications
Zong, Z., Wei, Y., Ren, J., Zhang, L., & Zhou, F. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01363-1 · Cited by 74
Combining Type I Interferons and 5-Aza-2′-Deoxycitidine to Improve Anti-Tumor Response against Melanoma
Lucarini, V., Buccione, C., Ziccheddu, G., Peschiaroli, F., Sestili, P., Puglisi, R., Mattia, G., Zanetti, C., Parolini, I., Bracci, L., et al. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.08.024 · Cited by 73
Functional, signalling and transcriptional differences of three distinct type I IFNs in a perciform fish, the mandarin fish Siniperca chuatsi
Laghari, Z. A., Chen, S. N., Li, L., Huang, B., Gan, Z., Zhou, Y., Huo, H. J., Hou, J., & Nie, P. (2018) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2018.02.008 · Cited by 73
Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown
Zhang, Y., Xie, X., Yeganeh, P. N., Lee, D.-J., Valle‐García, D., Meza‐Sosa, K. F., Junqueira, C., Su, J., Luo, H. R., Hide, W., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2022830118 · Cited by 73
cGAS–STING cytosolic DNA sensing pathway is suppressed by JAK2-STAT3 in tumor cells
Suter, M. A., Tan, N. Y., Thiam, C. H., Khatoo, M., MacAry, P. A., Angeli, V., Gasser, S., & Zhang, Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-86644-x · Cited by 72
Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype
Hiltbrunner, S., Cords, L., Kasser, S., Freiberger, S. N., Kreutzer, S., Toussaint, N. C., Grob, L., Opitz, I., Messerli, M., Zoche, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40745-5 · Cited by 78
Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T cell control of pancreatic cancer
Chibaya, L., DeMarco, K. D., Lusi, C. F., Kane, G. I., Brassil, M. L., Parikh, C. N., Murphy, K. C., Chowdhury, S. R., Li, J., Ma, B., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adj9366 · Cited by 74
Immunology of Plasmacytoid Dendritic Cells in Solid Tumors: A Brief Review
Koucký, V., Bouček, J., & Fialová, A. (2019) · Cancers · doi:10.3390/cancers11040470 · Cited by 75
Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models
Holl, E. K., Brown, M. C., Boczkowski, D., McNamara, M. A., George, D. J., Bigner, D. D., Gromeier, M., & Nair, S. K. (2016) · Oncotarget · doi:10.18632/oncotarget.12975 · Cited by 71
Systemically Administered TLR7/8 Agonist and Antigen-Conjugated Nanogels Govern Immune Responses against Tumors
Stickdorn, J., Stein, L., Arnold-Schild, D., Hahlbrock, J., Medina‐Montano, C., Bartneck, J., Ziß, T., Montermann, E., Kappel, C., Hobernik, D., et al. (2022) · ACS Nano · doi:10.1021/acsnano.1c10709 · Cited by 70
The SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation
Nakamura, A., Grossman, S., Song, K., Xega, K., Zhang, Y., Cvet, D., Berger, A., Shapiro, G., & Huszar, D. (2022) · Blood · doi:10.1182/blood.2021014267 · Cited by 70
Immune-modulators to combat hepatitis B virus infection: From IFN-α to novel investigational immunotherapeutic strategies
Isorce, N., Lucifora, J., Zoulim, F., & Durantel, D. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.08.008 · Cited by 75
Is there a causal link between PTEN deficient tumors and immunosuppressive tumor microenvironment?
Çetintaş, V. B., & Batada, N. N. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02219-w · Cited by 69
Immunological conversion of solid tumours using a bispecific nanobioconjugate for cancer immunotherapy
Lü, Y., Huntoon, K. M., Lee, D., Wang, Y., Ha, J., Qie, Y., Li, X., Schrank, B. R., Dong, S., Gallup, T. D., et al. (2022) · Nature Nanotechnology · doi:10.1038/s41565-022-01245-7 · Cited by 69
Nanoparticles Presenting Potent TLR7/8 Agonists Enhance Anti-PD-L1 Immunotherapy in Cancer Treatment
Autzen, A. A. A., Gale, E. C., Roth, G. A., Maikawa, C. L., Correa, S., Yu, A. C., & Appel, E. A. (2020) · Biomacromolecules · doi:10.1021/acs.biomac.0c00812 · Cited by 70
Exploiting immune-dependent effects of microtubule-targeting agents to improve efficacy and tolerability of cancer treatment
Serpico, A. F., Visconti, R., & Grieco, D. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2567-0 · Cited by 70
Cytokines in oncolytic virotherapy
Pol, J. G., Workenhe, S. T., Konda, P., Gujar, S. A., & Kroemer, G. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.10.007 · Cited by 71
Self-citation
Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling
Brown, M. C., Mosaheb, M., Mohme, M., McKay, Z. P., Holl, E. K., Kastan, J. P., Yang, Y., Beasley, G. M., Hwang, E., Ashley, D. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22088-1 · Cited by 70
Interactions between Type 1 Interferons and the Th17 Response in Tuberculosis: Lessons Learned from Autoimmune Diseases
Mourik, B. C., Lubberts, E., de Steenwinkel, J. E. M., Ottenhoff, T. H. M., & Leenen, P. J. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00294 · Cited by 68
Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity
van Wilpe, S., Tolmeijer, S. H., Koornstra, R. H. T., de Vries, I. J. M., Gerritsen, W. R., Ligtenberg, M. J. L., & Mehra, N. (2021) · Cancers · doi:10.3390/cancers13092249 · Cited by 67
Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer
Zhu, S., Ma, A.-H., Zhu, Z. G., Adib, E., Rao, T., Li, N., Ni, K., Chittepu, V. C. S. R., PRABHALA, R. H., Risco, J. G., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002917 · Cited by 66
Perturbation of Intracellular Cholesterol and Fatty Acid Homeostasis During Flavivirus Infections
Pombo, J. P. N., & Sanyal, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01276 · Cited by 68
Design, Synthesis, and Biological Evaluation of Amidobenzimidazole Derivatives as Stimulator of Interferon Genes (STING) Receptor Agonists
Xi, Q., Wang, M., Jia, W., Yang, M., Hu, J., Jin, J., Chen, X., Yin, D., & Wang, X. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01567 · Cited by 67
Copper‐Based Composites Nanoparticles Improve Triple‐Negative Breast Cancer Treatment with Induction of Apoptosis‐Cuproptosis and Immune Activation
Wang, N., Liu, Y., Peng, D., Zhang, Q., Zhang, Z., Xu, L., Yin, L., Zhao, X., Lu, Z., & Peng, J. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202401646 · Cited by 65
Cyto-Immuno-Therapy for Cancer: A Pathway Elicited by Tumor-Targeted, Cytotoxic Drug-Packaged Bacterially Derived Nanocells
Sagnella, S. M., Yang, L., Stubbs, G. E., Boslem, E., Martino‐Echarri, E., Smolarczyk, K., Pattison, S. L., Vanegas, N., Clair, E. S., Clarke, S. J., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.02.001 · Cited by 64
The role of dendritic cells in tumor microenvironments and their uses as therapeutic targets
Kim, C. W., Kim, K., & Lee, H. K. (2021) · BMB Reports · doi:10.5483/bmbrep.2021.54.1.224 · Cited by 66
Tumor-Derived Lysophosphatidic Acid Blunts Protective Type I Interferon Responses in Ovarian Cancer
Chae, C.-S., Sandoval, T. A., Hwang, S., Park, E. S., Giovanelli, P., Awasthi, D., Salvagno, C., Emmanuelli, A., Tan, C., Chaudhary, V., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1181 · Cited by 68
Potent Lymphatic Translocation and Spatial Control Over Innate Immune Activation by Polymer–Lipid Amphiphile Conjugates of Small‐Molecule TLR7/8 Agonists
Vrieze, J. D., Louage, B., Deswarte, K., Zhong, Z., Coen, R. D., Herck, S. V., Nuhn, L., Frich, C. K., Zelikin, A. N., Lienenklaus, S., et al. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201905687 · Cited by 64
Type I Interferon Regulates a Coordinated Gene Network to Enhance Cytotoxic T Cell–Mediated Tumor Killing
Fan, J.-B., Miyauchi, S., Xu, H., Liu, D., Kim, L. J. Y., Burkart, C., Cheng, H., Arimoto, K., Yan, M., Zhou, Y., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0608 · Cited by 63
The Inflammatory Milieu of Adamantinomatous Craniopharyngioma and Its Implications for Treatment
Whelan, R., Prince, E. W., Gilani, A., & Hankinson, T. C. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020519 · Cited by 63
Sialic acid conjugate-modified liposomes enable tumor homing of epirubicin via neutrophil/monocyte infiltration for tumor therapy
Ding, J., Sui, D., Liu, M., Su, Y., Wang, Y., Liu, M., Luo, X., Liu, X., Deng, Y., & Song, Y. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.07.063 · Cited by 63
cGAS/STING signalling pathway in senescence and oncogenesis
Yu, L., & Liu, P. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.08.007 · Cited by 67
Engineering innate immune cells for cancer immunotherapy
Tarannum, M., Ding, X., Barisa, M., Hu, S., Anderson, J., Romee, R., & Zhang, J. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02629-5 · Cited by 64
Mutations in DNA repair genes are associated with increased neo-antigen load and activated T cell infiltration in lung adenocarcinoma
Chae, Y. K., Anker, J. F., Bais, P., Namburi, S., Giles, F. J., & Chuang, J. H. (2017) · Oncotarget · doi:10.18632/oncotarget.23742 · Cited by 65
Emerging roles of DYRK2 in cancer
Tandon, V., de la Vega, L., & Banerjee, S. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev120.015217 · Cited by 63
Human autoantibodies neutralizing type I IFNs: From 1981 to 2023
Bastard, P., Gervais, A., Voyer, T. L., Philippot, Q., Cobat, A., Rosain, J., Jouanguy, E., Abel, L., Zhang, S., Zhang, Q., et al. (2024) · Immunological Reviews · doi:10.1111/imr.13304 · Cited by 66
High‐risk HPV oncoproteins E6 and E7 and their interplay with the innate immune response: Uncovering mechanisms of immune evasion and therapeutic prospects
Cigno, I. L., Calati, F., Girone, C., Catozzo, M., & Gariglio, M. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29685 · Cited by 65

Authors: Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J., & Kroemer, G.
Affiliations: Université Paris-Sud (FR)
Inserm (FR)
The University of Queensland (AU)
Corresponding author: Kroemer, Guido
ORCID: Zitvogel, Laurence
Galluzzi, Lorenzo
Kepp, Oliver
Smyth, Mark J.
Kroemer, Guido
Venue: Nature Reviews Immunology
Publisher: Springer Science and Business Media LLC
Published: 2015-06-01
Volume: 15
Issue: 7
Pages: 405-414
ISSN: 1474-1733 (ISSN-L)
1474-1741
DOI: 10.1038/nri3845
OpenAlex: W1611944043
Cited by: 1,305
References: 128
Citations by year: 2026: 85 · 2025: 123 · 2024: 162 · 2023: 161 · 2022: 155 · 2021: 121 · 2020: 126 · 2019: 87 · 2018: 104 · 2017: 94 · 2016: 69 · 2015: 17
FWCI: 8.94
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature reviews. Immunology (publishedVersion)
PubMed (publishedVersion)
Funders: Association pour la Recherche sur le Cancer
Ligue Contre le Cancer
Institut National Du Cancer
Institute of Cancer Research
Topics: Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords: type I interferon, antitumor immunity, tumor surveillance, IFN-stimulated genes, oncolytic viruses, immunoadjuvant, chemotherapeutics, targeted anticancer agents, recombinant interferon, cancer immunotherapy
MeSH terms: Animals, Humans, Immunotherapy, Interferon Type I, Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Type I interferons in anticancer immunity

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks